Editor: Mahmut Akgul (

2022-15/April 11
Contributors: Ankur Sangoi

A male in his 60s with history of prostate cancer status post radiation treatment. Transurethral resection of the prostate is performed.


1. What is the correct diagnosis?

a) Treated prostatic adenocarcinoma

b) Sarcomatoid urothelial carcinoma

c) Inflammatory myofibroblastic tumor

d) Fibromyxoid nephrogenic adenoma

1.Fibrimyxoid nephrogenic adenoma.

The lesional cells in the case were positive for keratin and PAX8, with negative staining for GATA3, NKX3.1, or p63. The background amyloid-like foci (often seen in this diagnosis) were negative for amyloid by Congo red stain.

The correct diagnosis is fibromyxoid nephrogenic adenoma, a rare but reported morphologic pattern of nephrogenic adenoma. On H&E, the most useful feature is searching for classic tubular pattern nephrogenic adenoma, usually present (but can be focal) among the spindle cells and myxoinflammatory background. There should be minimal atypia and/or mitosis. Interestingly, in the largest series of fibromyxoid nephrogenic adenomas, most of the cases occurred in a post-treatment setting of prostate cancer. As such, the key diagnostic pitfall is treated prostatic adenocarcinoma, although sarcomatoid urothelial carcinoma is also in the differential.

Immunohistochemically, this variant stains like other nephrogenic adenoma patterns, being positive for PAX8 and negative for NKX3.1. As a cautionary reminder, GATA3, AMACR, PSAP, and PSA can be positive in nephrogenic adenoma.

Hansel DE, Nadasdy T, Epstein JI. Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma. Am J Surg Pathol. 2007 Aug;31(8):1231-7.

Ankur Sangoi
El Camino Hospital, Mountain View, CA


nephrogenic adenoma, fibromyxoid, post-treatment prostatic adenocarcinoma.